RENOQUID
LOE Approachingsulfacytine
NDAORALTABLETPriority Review
Approved
Sep 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENOQUID (sulfacytine) is an oral sulfonamide antibiotic tablet approved in 1975 for urinary tract infections. Sulfacytine is a short-acting sulfonamide that inhibits bacterial dihydropteroate synthase, disrupting folate synthesis. It is indicated for treating uncomplicated urinary tract infections caused by susceptible gram-negative and gram-positive bacteria.
LOE Approaching
As LOE approaches with moderate competitive pressure (30), the brand team is likely in defensive/transition mode with reduced headcount and focus shifting to managed care and retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RENOQUID offers limited growth trajectory but provides stability in a legacy franchise requiring defensive commercial strategies and managed care expertise. Career development is constrained by the product's maturity and approaching LOE, making it suitable for experienced professionals managing market transition rather than early-career advancement.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.